Topic: flu vaccine

Here is some other vaccine news of note for the week.

A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.

The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.

Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.

Having missed two flu seasons, AZ has swapped out FluMist's H1N1 component, which was linked to low efficacy that led to previous CDC rejections.

After examining GSK's internal safety reports, The BMJ suggests serious safety signal had emerged for Pandemrix but was not made public.

Here is some other vaccine news of note for the week.